Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

Sowa5000 Mar. 13 at 2:43 PM

$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!

1 · Reply

teaman60 Mar. 13 at 2:17 PM

$RLMD Uh oh, zacks shorting this. Always a bad sign

0 · Reply

ZacksResearch Mar. 12 at 5:34 PM

$RLMD surges 42% in a week — what's fueling the rally? 🚀 Positive interim data from RLMD's phase II study shows a 76% 12-month complete response rate for NMIBC patients, with an 80% rate in the BCG-unresponsive subgroup. The candidate demonstrated strong durability and favorable safety, setting the stage for a phase III RESCUE program targeting two NMIBC settings. Discover the full potential of RLMD's NDV-01 here 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-body-37238&ADID=SYND_STOCKTWITS_TWEET_2_2883316_BODY_37238

0 · Reply

ZacksResearch Mar. 12 at 4:34 PM

$RLMD just ripped 42% in a week — and the catalyst is clinical data. 🚀 Relmada Therapeutics reported encouraging efficacy and safety results from a mid-stage bladder cancer study of NDV-01 and simultaneously outlined plans for a phase III trial. See what’s driving the momentum 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-teaser-37226&ADID=SYND_STOCKTWITS_TWEET_2_2883316_TEASER_37226

0 · Reply

shehww Mar. 12 at 4:26 PM

$RLMD

0 · Reply

shehww Mar. 12 at 3:55 PM

$RLMD

0 · Reply

teaman60 Mar. 12 at 1:32 PM

$RLMD Acting as I said it would. $5.25 By next Friday and should bottom at $4.75

0 · Reply

teaman60 Mar. 11 at 7:11 PM

$RLMD I know my penny stocks lol

0 · Reply

AdvancedOperati Mar. 11 at 3:58 PM

$RLMD appliedmarketconcepts.us/systematic-trading-concepts-library.html

0 · Reply

teaman60 Mar. 11 at 3:52 PM

$RLMD As expected, it will retrace at least 50% of Mondays gains. It's a penny stock

0 · Reply

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 9, 2026, 4:30 PM EDT - 6 days ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mar 9, 2026, 7:05 AM EDT - 7 days ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:00 AM EDT - 7 days ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Jan 12, 2026, 7:00 AM EST - 2 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Dec 3, 2025, 7:30 AM EST - 3 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 4 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 4 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 4 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 4 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 4 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 6 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 6 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 7 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 8 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 8 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 10 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 10 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 11 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 11 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Sowa5000 Mar. 13 at 2:43 PM

$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!

1 · Reply

teaman60 Mar. 13 at 2:17 PM

$RLMD Uh oh, zacks shorting this. Always a bad sign

0 · Reply

ZacksResearch Mar. 12 at 5:34 PM

0 · Reply

ZacksResearch Mar. 12 at 4:34 PM

0 · Reply

shehww Mar. 12 at 4:26 PM

$RLMD

0 · Reply

shehww Mar. 12 at 3:55 PM

$RLMD

0 · Reply

teaman60 Mar. 12 at 1:32 PM

$RLMD Acting as I said it would. $5.25 By next Friday and should bottom at $4.75

0 · Reply

teaman60 Mar. 11 at 7:11 PM

$RLMD I know my penny stocks lol

0 · Reply

AdvancedOperati Mar. 11 at 3:58 PM

$RLMD appliedmarketconcepts.us/systematic-trading-concepts-library.html

0 · Reply

teaman60 Mar. 11 at 3:52 PM

$RLMD As expected, it will retrace at least 50% of Mondays gains. It's a penny stock

0 · Reply

CrestFresh Mar. 11 at 1:58 PM

$RLMD cooking up some day 3 action perhaps?

0 · Reply

shehww Mar. 11 at 1:53 PM

$RLMD I expected more; these fluctuations are quite normal. RLM is partly shorted, and stop-loss orders are also triggered, causing the price to dip slightly. The news was very good, and with an additional 160 million private investors, I think it will reach at least 8 or 9 in the next few days. This is not a buy or sell recommendation; everyone has to decide for themselves what to do with their investment.

0 · Reply

Minnie23 Mar. 11 at 1:33 PM

$RLMD can we run today ?

0 · Reply

mendez628 Mar. 10 at 8:53 PM

$RLMD with the PIPE closing tomorrow, will this go up?

0 · Reply

teaman60 Mar. 10 at 7:36 PM

$RLMD Sadly under 6 by weds or Thursday. It got pumped pretty hard and will give back 50% which is puts in in a range of 5. 60-$5.85

0 · Reply

luminouslumens Mar. 10 at 6:13 PM

$VNDA $RXRX $RLMD other notable bios making the leaderboard today

0 · Reply

teaman60 Mar. 10 at 6:01 PM

$RLMD BTW, the early hump u saw at opening was the MMs snagging bagholders. This is your typical penny stock

0 · Reply

teaman60 Mar. 10 at 5:51 PM

$RLMD As I predicted. This will not hold $6 this week. In 2 weeks will be low 5s

0 · Reply

Stackdoe101 Mar. 10 at 5:40 PM

$RLMD 🙃✨️

0 · Reply

trade_goats Mar. 10 at 5:24 PM

$BIAF setup reminds me of $RLMD chart from yesterday

0 · Reply

drivinglate Mar. 10 at 5:16 PM

$RLMD https://m.investing.com/news/transcripts/relmada-therapeutics-at-leerink-global-strategic-shift-to-urooncology-93CH-4552535?ampMode=1

0 · Reply

Minnie23 Mar. 10 at 2:52 PM

$RLMD it need to get over 7 for a good day

1 · Reply

Market Cap	433.40M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,131,279
Avg Vol	1,563,014
Day's Range	N/A - N/A
Shares Out	73.33M
Stochastic %K	51%
Beta	0.72
Analysts	Strong Sell
Price Target	$10.75